EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors

Sarah Gold, Ali Shilatifard

Current Opinion in Genetics & Development · 2024-06 · 86 · 102181

DOI: 10.1016/j.gde.2024.102181 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Opinion in Genetics & Development, 2024-06. Verfasst von Sarah Gold und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Genetics, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Ch…. Hauptthemen laut MEDLINE: Transcription Factors, Epigenesis, Genetic, Neoplasms, Cell Cycle Proteins. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 83 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Development of cancer therapies targeting chromatin modifiers and transcriptional regulatory factors is rapidly expanding to include new targets and novel targeting strategies. At the same time, basic molecular research continues to refine our understanding of the epigenetic mechanisms regulating transcription, gene expression, and oncogenesis. This mini-review focuses on cancer therapies targeting the chromatin-associated factors that recognize histone lysine acetylation. Recently reported safety and efficacy are discussed for inhibitors targeting the bromodomains of bromodomain and extraterminal domain (BET) family proteins. In light of recent results indicating that the transcriptional regulator BRD4-PTEFb can function independently of BRD4's bromodomains, the clinical trial performance of these BET inhibitors is placed in a broader context of existing and potential strategies for targeting BRD4-PTEFb. Recently developed therapies targeting bromodomain-containing factors within the SWI/SNF (BAF) family of chromatin remodeling complexes are discussed, as is the potential for targeting the bromodomain-containing transcription factor TAF1 and the YEATS acetylrecognition domain-containing factor GAS41. Recent findings regarding the selectivity and combinatorial specificity of acetylrecognition are highlighted. In conclusion, the potential for further development is discussed with a focus on proximity-based therapies targeting this class of epigenetic factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcription FactorsEpigenesis, GeneticNeoplasmsCell Cycle ProteinsNuclear ProteinsHumansAcetylationProtein DomainsMolecular Targeted TherapyHistonesChromatinTATA-Binding Protein Associated FactorsTranscription Factor TFIIDChromatin Assembly and DisassemblyAnimalsBromodomain Containing ProteinsProteinsHistone Acetyltransferases

Substanzen

Transcription FactorsCell Cycle ProteinsNuclear ProteinsBRD4 protein, humanHistonesTATA-binding protein associated factor 250 kDaChromatinTATA-Binding Protein Associated FactorsTranscription Factor TFIIDbromodomain and extra-terminal domain protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Genetics, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: https://twitter.com/@rwx_lif…
  • Department of Biochemistry and Molecular Genetics, Simpson Querrey Institute for Epigenetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: ASH@northwestern.edu.

Zitieren

APA

Gold, S., & Shilatifard, A. (2024). Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors. Current Opinion in Genetics & Development, 86, 102181. https://doi.org/10.1016/j.gde.2024.102181

Vancouver

Gold S, Shilatifard A. Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors. Current Opinion in Genetics & Development. 2024;86:102181. doi:10.1016/j.gde.2024.102181

BibTeX
@article{Gold2024,
  author = {Gold, Sarah and Shilatifard, Ali},
  title = {Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain–containing factors},
  journal = {Current Opinion in Genetics & Development},
  year = {2024},
  volume = {86},
  pages = {102181},
  doi = {10.1016/j.gde.2024.102181}
}
Kostenlos starten →